We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Jeff Sessions’ Replacement Could Show Marijuana Stocks the Grass Isn’t Always Greener on the Other Side

Don’t count on improvement in the U.S. legal environment for the cannabis industry with a new attorney general.

You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.

This article was originally published on Fool.com

It’s not always a great thing to get what you wished for.

Should you buy Rolls Royce shares today?

Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from US tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.

That’s why this could be an ideal time to secure this valuable research – Mark’s analysts have scoured the markets to reveal 5 of his favourite long-term ‘Buys’. Please, don’t make any big decisions before seeing them.

The marijuana industry has looked forward to Jeff Sessions stepping down as U.S. attorney general ever since he was named to the position by President Trump. Their wish came true last week: Trump asked for and received Sessions’ resignation. The immediate reaction by marijuana stocks was tremendous — even for Canadian marijuana stocks like Canopy Growth and Tilray that weren’t really impacted all that much by Sessions’ departure.

But the celebrations could be short lived. The names of the potential candidates to replace Jeff Sessions have begun to leak out to the press. Based on the list of picks that have been identified, the new attorney general could prove to marijuana stocks that the grass isn’t always greener on the other side. Here are five top candidates Trump is reportedly considering and the stance of each on marijuana.

The White House with storm clouds in background.

IMAGE SOURCE: GETTY IMAGES.

1. Alex Azar

Several sources have included current Secretary of Health and Human Services (HHS) Alex Azar as a possible replacement for Jeff Sessions. Azar’s background includes serving as a clerk for former Supreme Court Justice Antonin Scalia, serving as general counsel and deputy secretary of HHS during the George W. Bush administration, and working as an executive with Eli Lilly.

Azar doesn’t sound like a proponent of relaxing marijuana laws. In March, he stated that “there really is no such thing as medical marijuana.” He added: “There is no FDA approved use of marijuana, a botanical plant. I just want to be very clear about that.” His comment came before the FDA approved GW Pharmaceuticals‘ Epidiolex, a cannabidiol (CBD) product made from marijuana, for treating two rare forms of epilepsy.

2. Pam Bondi

CNN, The Wall Street Journal, and other news organizations have listed Florida Attorney General Pam Bondi as a top pick to take Jeff Sessions’ spot. Bondi previously served as an assistant state’s attorney in Florida.

After a circuit judge ruled that Florida’s ban on smoking medical marijuana was unconstitutional, Bondi’s office filed a 57-page document supporting the ban. The Florida attorney general’s office also argued against the circuit court decision before an appeals court. However, Bondi did issue an emergency rule on Nov. 1, 2018, to clear the way for patients in Florida to obtain Epidiolex. 

3. Chris Christie

Former New Jersey governor Chris Christie has been a close advisor to President Trump for several years and has expressed interest in the U.S. attorney general position in the past. Christie could now be a leading contender to replace Jeff Sessions.

While he was governor of New Jersey, Christie stated that supporters of marijuana legalization wanted to “poison our kids” and referred to potential tax revenue stemming from sales of legalized marijuana as “blood money.” During his 2016 presidential campaign, he promised to crack down on states that had violated federal laws by legalizing marijuana. However, Christie recently stated that “states have the right to do what they want to do” on marijuana.

4. Rudy Giuliani

Another famous advisor to President Trump who was interested in being named U.S. attorney general two years ago could be in the running. Former New York City mayor Rudy Giuliani has been listed by multiple news organizations as a potential Trump favorite to head the U.S. Department of Justice.

As mayor of New York City, Giuliani took a hard-line approach on marijuana, directing the police to make arrests for possession of small amounts of the drug. He has also fervently opposed the legalization of marijuana, including medical marijuana, in the past.

5. John Ratcliffe

NBC News has reported that Rep. John Ratcliffe (R.-Texas) is another potential front-runner to replace Jeff Sessions. Ratcliffe previously served as U.S. attorney of the Eastern District of Texas.

Ratcliffe cosponsored the Charlotte’s Web Medical Access Act that would have exempted CBD from federal marijuana prohibitions. However, he has voted against all other major marijuana reform legislation so far in his congressional career.

How much does it matter?

There are other potential candidates to fill the U.S. attorney general slot as well. The big question for marijuana stocks is: Does it really matter who Trump picks?

For Canadian marijuana stocks like Canopy Growth and Tilray, the answer to that question really is “no.” These companies don’t operate in the U.S. and won’t until federal marijuana laws are changed. The U.S. attorney general can’t change those laws.

The primary way that the U.S. attorney general can impact the large Canadian marijuana growers is by preventing or blocking exports of medical cannabis to be included in clinical studies conducted in the U.S. But even under Jeff Sessions, both Canopy Growth and Tilray were allowed to supply medical cannabis for U.S. clinical studies.

But what about for U.S. marijuana businesses? Jeff Sessions’ replacement will determine how aggressively the Department of Justice will prosecute current federal marijuana laws. Sessions chose to rescind Obama-era policies that kept the DOJ from intervening in states that had legalized marijuana.

However, it’s important to remember that President Trump himself has indicated a willingness to support legislation that would leave marijuana laws to the individual states. It doesn’t seem likely that the new attorney general, regardless of who it is, would oppose Trump in this area. He or she is likely to walk a tightrope on another front — the ongoing Mueller investigation — and probably would be eager to be in alignment with the president in other areas.

In the big scheme of things, the next U.S. attorney general might impact marijuana stocks less than expected by many. But it’s entirely possible that the current precarious environment for the U.S. cannabis industry put into place by Jeff Sessions won’t get any better for a while to come.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

 

More on Investing Articles

Abstract bull climbing indicators on stock chart
Investing Articles

FTSE 250 stock CMC’s shares have rocketed 51%! What’s going on?

CMC Markets' shares have surged by double-digits today after a strong full-year trading update. Is the FTSE 250 company now…

Read more »

A row of satellite radars at night
Investing Articles

Will I buy SpaceX at £100 a share in my SIPP?

Ben McPoland is considering adding SpaceX stock to his SIPP on 12 June. Might this be a no-brainer buy-and-hold opportunity?

Read more »

Young brown woman delighted with what she sees on her screen
Investing Articles

Aberdeen shares are back in the FTSE 100 — is this turnaround stock just getting started?

Following its return to the FTSE 100, Andrew Mackie examines whether Aberdeen's shares could be on the cusp of a…

Read more »

Shot of an young mixed-race woman using her cellphone while out cycling through the city
Investing Articles

Down 65% with a 5.65% yield! Is this dividend share a once-in-a-decade buy? 

Harvey Jones says this dividend share is still posting decent profits at a challenging time. Its low valuation and high…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Dividend Shares

This is the worst FTSE 100 share over 5 years. Should I sell it?

The worst-performing share in the FTSE 100 has lost two-thirds of its value in the past five years. I own…

Read more »

Arrow symbol glowing amid black arrow symbols on black background.
Investing Articles

Microsoft’s share price is storming back and it’s not too late to consider buying

Microsoft’s share price has jumped 20% in the blink of an eye. Edward Sheldon believes it can go higher, however,…

Read more »

British pound data
Investing Articles

What’s your plan for a stock market crash?

The stock market might be flying, but the time to think about a crash is before it happens. Fortunately, it…

Read more »

Investing Articles

Will SpaceX stock explode on entry?

The SpaceX IPO is just days away and excitement about the stock has gone into orbit. Harvey Jones is urging…

Read more »